证券代码：688098 证券简称：申联生物 公告编号：2025-028 申联生物医药（上海）股份有限公司 2025 年 1-6 月募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 申联生物医药（上海）股份有限公司董事会根据中国证券监督管理委员会（以 下简称"证监会"）《上市公司募集资金监管规则》及《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》等相关法律、法规及规范性文件的 规定，编制了《2025 年 1-6 月关于公司首次公开发行 A 股股票募集资金存放与 实际使用情况的专项报告》。现将截至 2025 年 6 月 30 日公司募集资金存放与实 际使用情况专项说明如下： 一、 募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据证监会作出的《关于同意申联生物医药（上海）股份有限公司首次公开 发行股票注册的批复》（证监许可[2019]1743 号），同意公司向社会公开发行人 民币普通股（A 股）5,000 万股。公司于 2019 年 10 月 28 日完成了首次公开 ...

申联生物医药（上海）股份有限公司 2025年度"提质增效重回报"行动方案的半年度评估报告 为积极响应国家关于推动生物医药产业高质量发展及资本市场"提质增效 重回报"的政策号召，申联生物医药（上海）股份有限公司（以下简称"公 司"）结合自身发展战略于2025年4月30日发布了《2025年度"提质增效重回 报"行动方案》。2025年上半年，公司根据行动方案内容，积极开展和落实各 项工作，现将2025年上半年的主要工作成果报告如下： 一、拓展业务边界，进军人用创新药领域 此外，依托于公司完备的研发资质，报告期内公司正式启动并推进对外临 床试验委托服务，为行业伙伴提供专业的兽药临床试验方案设计、执行与管理 服务，形成新的业务增长点。 2025年上半年，公司紧紧围绕"建设世界一流高科技生物公司"的战略愿 景，依托多元化的生物医药技术平台及人才储备，不断拓展业务边界，积极布 局人用创新药领域，着力培育企业增长新动能。公司通过全资子公司上海本天 成生物医药有限公司（简称"本天成"）向扬州世之源生物科技有限责任公司 （简称"世之源"）增资6,000万元，持股比例达20.48%。 世之源致力于创新药物的研发、临床申报及临床试验 ...

Market Overview - The animal health sector experienced a decline of 0.5% on August 29, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Individual Stock Performance - The top performer in the animal health sector was Qudongli (code: 838275), with a closing price of 11.87 and an increase of 7.23% [1] - Other notable gainers included Yongshun Biological (code: 839729) with a 1.34% increase and Ruipu Biological (code: 300119) with a 0.81% increase [1] - Conversely, *ST Lvkang (code: 002868) saw a significant decline of 3.24%, closing at 26.32 [2] Trading Volume and Capital Flow - The total net outflow of main funds in the animal health sector was 53.36 million yuan, while retail funds saw a net inflow of 29.48 million yuan [2] - The trading volume for Qudongli was 92,700 hands, with a transaction amount of 108 million yuan [1] Fund Flow Analysis - *ST Lvkang experienced a net outflow of 11.85 million yuan from main funds, representing a 24.27% net share [3] - In contrast, retail funds for *ST Lvkang saw a net inflow of 7.44 million yuan, accounting for 15.25% of its total [3] - Other companies like Shenglian Biological and Zhongmu Co. also faced net outflows from main funds, indicating a trend of capital withdrawal in the sector [3]

Market Overview - The animal health sector experienced a decline of 1.01% on August 28, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.07, up 5.23% [1] - Xianfeng Holdings (002141) at 4.19, up 1.21% [1] - Zhongmu Co. (600195) at 7.63, up 0.66% [1] - Major decliners included: - *ST Lvkang (002868) at 27.20, down 3.51% [2] - Shenyuan Bio (688098) at 12.59, down 2.70% [2] - KQ Bio (688526) at 18.40, down 1.55% [2] Capital Flow - The animal health sector saw a net outflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of 101 million yuan [2] - The detailed capital flow for key stocks showed: - Zhongmu Co. had a net outflow of 18.59 million yuan from institutional investors [3] - *ST Lvkang experienced a significant net outflow of 7.31 million yuan from institutional investors [3] - Retail investors showed a net inflow of 5.64 million yuan into *ST Lvkang [3]

Market Overview - The animal health sector experienced a slight decline of 0.03% on August 26, with Shenlian Biological leading the drop [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] Stock Performance - Key stocks in the animal health sector showed varied performance: - KQ Bio (688526) rose by 6.80% to close at 19.33, with a trading volume of 167,100 shares and a turnover of 327 million yuan [1] - Huisheng Biological (300871) increased by 1.48% to 24.00, with a trading volume of 160,900 shares and a turnover of 387 million yuan [1] - Shenlian Biological (688098) fell by 8.41% to 13.28, with a trading volume of 313,100 shares and a turnover of 433 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 68.22 million yuan from institutional investors, while retail investors had a net inflow of 76.14 million yuan [2][3] - Notable capital flows for specific stocks include: - Huisheng Biological had a net outflow of 56.08 million yuan from institutional investors [3] - Zhongmu Co. (600195) experienced a net inflow of 3.88 million yuan from institutional investors [3] - KQ Bio had a net outflow of 20.91 million yuan from institutional investors [3]

Market Overview - On August 25, the animal health sector rose by 1.47%, led by Shenlian Biological, while the Shanghai Composite Index closed at 3883.56, up 1.51%, and the Shenzhen Component Index closed at 12441.07, up 2.26% [1]. Stock Performance - Shenlian Biological (688088) closed at 14.50, with a significant increase of 13.81% and a trading volume of 521,000 shares, amounting to 723 million yuan [1]. - Other notable stocks included: - KQ Biological (688526) at 18.10, up 2.67% [1]. - Dayu Biological (871970) at 10.25, up 1.18% [1]. - Huisheng Biological (300871) at 23.75, up 0.93% [1]. - Ruip Biological (300119) at 23.48, up 0.86% [1]. - Jinhai Biological (002688) at 7.31, up 0.55% [1]. Capital Flow - The animal health sector experienced a net outflow of 40.13 million yuan from institutional investors, while retail investors saw a net outflow of 60.97 million yuan. Conversely, speculative funds had a net inflow of 101 million yuan [2]. Individual Stock Capital Flow - Shenlian Biological had a net inflow of 35.39 million yuan from institutional investors, while retail investors faced a net outflow of 74.83 million yuan [3]. - Other stocks with notable capital flows included: - Pulaike (603566) with a net inflow of 3.28 million yuan from institutional investors and a net outflow of 9.68 million yuan from retail investors [3]. - Huisheng Biological (300871) had a net inflow of 2.55 million yuan from institutional investors but a net outflow of 13.77 million yuan from retail investors [3].

天眼查商业履历信息显示，申联生物医药(上海)股份有限公司，成立于2001年，位于上海市，是一家以 从事医药制造业为主的企业。企业注册资本41064.4万人民币，实缴资本31689.7548万人民币。公司法定 代表人为聂东升。 通过天眼查大数据分析，申联生物医药(上海)股份有限公司共对外投资了7家企业，参与招投标项目 1618次，知识产权方面有商标信息31条，专利信息143条，此外企业还拥有行政许可53个。 来源：金融界 金融界消息 截至2025年8月25日收盘，申联生物（688098）报收于14.5元，上涨13.81%，换手率 12.69%，成交量52.10万手，成交金额7.23亿元。 资金流向方面，今日主力资金净流入3539.32万元，占比成交额4.9%。其中，超大单净流出1070.38万 元、占成交额1.48%，大单净流入4609.70万元、占成交额6.38%，中单净流出流入3943.95万元、占成交 额5.46%，小单净流出7483.27万元、占成交额10.35%。 申联生物最新一期业绩显示，截至2025一季报，公司营业总收入7874.11万元、同比减少10.58%，归属 净利润301.99万元，同比减 ...

Group 1 - The animal vaccine sector experienced a decline of 0.72% as of the market close on August 22, ranking among the top declines in concept sectors [1] - Within the animal vaccine sector, companies such as Shenlian Biological, Weilan Biological, and Xianfeng Holdings saw significant declines, while Kexing Pharmaceutical, Haizheng Pharmaceutical, and Guoyao Modern recorded increases of 2.06%, 0.44%, and 0.09% respectively [1] - The overall market saw a net outflow of 0.68 billion yuan from the animal vaccine sector, with 11 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top net outflow in the animal vaccine sector was from Kanghua Biological, with a net outflow of 30.50 million yuan, followed by Shenlian Biological, Dabeinong, and Jinhai Biological with outflows of 27.38 million yuan, 24.27 million yuan, and 23.53 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included Haizheng Pharmaceutical, Kexing Pharmaceutical, and Luoniushan, with net inflows of 27.34 million yuan, 16.70 million yuan, and 10.38 million yuan respectively [3] - The trading activity in the animal vaccine sector showed that Kanghua Biological had a turnover rate of 3.52% and a decline of 1.70%, while Kexing Pharmaceutical had a turnover rate of 3.12% and an increase of 2.06% [3]

Market Overview - The animal health sector experienced a decline of 0.76% on August 22, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Individual Stock Performance - Yongshun Biological (code: 839729) closed at 11.18, down 4.36% with a trading volume of 91,600 shares and a turnover of 102 million yuan [1] - Dayu Biological (code: 871970) closed at 10.13, down 2.78% with a trading volume of 32,700 shares and a turnover of 33.49 million yuan [1] - Shunlian Biological (code: 688098) closed at 12.74, down 2.00% with a trading volume of 317,600 shares and a turnover of 412 million yuan [1] - Other notable declines include Xianfeng Holdings (code: 002141) down 1.79% and Jinhai Biological (code: 002688) down 1.36% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 74.19 million yuan from institutional investors, while retail investors had a net inflow of 91.60 million yuan [1] - Key stocks with significant capital flow include: - Huisheng Biological (code: 300871) with a net outflow of 9.62 million yuan from institutional investors [2] - Kexin Biological (code: 688526) with a net inflow of 7.28 million yuan from institutional investors [2] - ST Lvkang (code: 002868) had a net outflow of 3.99 million yuan from institutional investors but a net inflow of 3.77 million yuan from retail investors [2]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 839729 | 永顺生物 | 11.69 | 9.87% | 14.71万 | | 1.64亿 | | 002868 | *ST绿康 | 28.80 | 2.09% | 1.11万 | 3188.75万 | | | 871970 | 大禹生物 | 10.42 | 1.46% | 4.61万 | 4797.93万 | | | 300119 | 瑞普生物 | 23.40 | 0.73% | 10.48万 | | 2.45亿 | | 600195 | 中牧股份 | 7.73 | 0.39% | 10.75万 | 8304.48万 | | | 603566 | 普莱柯 | 15.35 | 0.33% | 6.98万 | | 1.07亿 | | 603718 | 海利生物 | 7.34 | 0.00% | 11.72万 | 8607.48万 | | | 688526 | 科前生物 | 17.75 | 0.00% | 3.05万 | 5409 ...